cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Ikena Oncology Inc
3 own
2 watching
Current Price
$0
$-0.01
(-0.23%)
logo-ikna
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
155.54M
52-Week High
52-Week High
11.79
52-Week Low
52-Week Low
1.94
Average Volume
Average Volume
0M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization155.54M
icon52-Week High11.79
icon52-Week Low1.94
iconAverage Volume0M
iconDividend Yield--
iconP/E Ratio--
What does the Ikena Oncology Inc do?
Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, an oral inhibitor of aryl hydrocarbon receptor; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Read More
How much money does Ikena Oncology Inc make?
News & Events about Ikena Oncology Inc.
Ticker Report
2 months ago
Ikena Oncology (NASDAQ:IKNA Get Rating) had its price objective lowered by investment analysts at HC Wainwright from $26.00 to $22.00 in a research note issued to investors on Tuesday, The Fly reports. The brokerage currently has a buy rating on the stock. Separately, Credit ...
Zolmax
2 months ago
Ikena Oncology (NASDAQ:IKNA Get Rating) had its price objective lowered by investment analysts at HC Wainwright from $26.00 to $22.00 in a research note issued to investors on Tuesday, The Fly reports. The brokerage currently has a buy rating on the stock. Separately, Credit Suisse Group reduced ...
Globe Newswire
2 months ago
Novel best-in-class MEK-RAF complex inhibitor IK-595 targets RAS pathway; IND in 2023 Novel paralog-selective TEAD inhibitor IK-930 advancing as planned in dose escalation; clinical data in 2023 Company prioritizes advancement of targeted oncology portfolio; cash runway extended into 2025 BOSTON, ...
Globe Newswire
2 months ago
BOSTON, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, Ikena), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will present a corporate overview and participate in 1x1 investor meetings at the Piper ...
Ticker Report
2 months ago
Ikena Oncology, Inc. (NASDAQ:IKNA Get Rating) Equities research analysts at William Blair decreased their Q4 2022 EPS estimates for Ikena Oncology in a research note issued on Tuesday, November 8th. William Blair analyst M. Phipps now anticipates that the company will post earnings ...
Frequently Asked Questions
Frequently Asked Questions
What is Ikena Oncology Inc share price today?
plus_minus_icon
Can Indians buy Ikena Oncology Inc shares?
plus_minus_icon
How can I buy Ikena Oncology Inc shares from India?
plus_minus_icon
Can Fractional shares of Ikena Oncology Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Ikena Oncology Inc stocks?
plus_minus_icon
What is today’s traded volume of Ikena Oncology Inc?
plus_minus_icon
What is today’s market capitalisation of Ikena Oncology Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Ikena Oncology Inc?
plus_minus_icon
What percentage is Ikena Oncology Inc down from its 52-Week High?
plus_minus_icon
What percentage is Ikena Oncology Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0
$-0.01
(-0.23%)
logo-ikna
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00